Denali Therapeutics Inc. (DNLI) financial statements (2021 and earlier)

Company profile

Business Address 161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,470961550587415479479
Cash and cash equivalents507351137208798363
Short-term investments963610412380336397416
Receivables6      
Other undisclosed current assets20101018151517
Total current assets:1,496971559605430494496
Noncurrent Assets
Operating lease, right-of-use asset33333334343435
Property, plant and equipment41424445474747
Long-term investments and receivables3320710402456
Long-term investments3320710402456
Other noncurrent assets2442334
Total noncurrent assets:109998891123109142
TOTAL ASSETS:1,6041,070647696553603638
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities123161332522
Accounts payable1322324
Accrued liabilities 1287 1514
Employee-related liabilities 964 84
Deferred revenue20283425191823
Debt   4   
Other liabilities47   2432
Other undisclosed current liabilities45495   
Total current liabilities:721055848454747
Noncurrent Liabilities
Long-term debt and lease obligation64656768697071
Operating lease, liability64656768697071
Liabilities, other than long-term debt24172035444845
Deferred revenue23172035444845
Other liabilities1000000
Other undisclosed noncurrent liabilities294      
Total noncurrent liabilities:3828287103113118116
Total liabilities:454188145151158165162
Stockholders' equity
Stockholders' equity attributable to parent1,151883502545395438475
Common stock2211111
Additional paid in capital1,5041,4801,0411,025819808798
Accumulated other comprehensive income (loss)(0)011011
Accumulated deficit(354)(599)(541)(482)(426)(372)(325)
Total stockholders' equity:1,151883502545395438475
TOTAL LIABILITIES AND EQUITY:1,6041,070647696553603638

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Sublease income 111   
Gross profit:3179645144
Operating expenses(73)(70)(67)(64)(62)(64)(67)
Operating income (loss):244(60)(61)(60)(58)(50)(63)
Nonoperating income2233444
Investment income, nonoperating(1)  11  
Income (loss) from continuing operations before income taxes:246(58)(59)(57)(54)(46)(59)
Income tax expense (benefit) (0)(0)0(0)00
Other undisclosed income from continuing operations1      
Net income (loss):247(58)(59)(57)(54)(46)(58)
Other undisclosed net loss attributable to parent(2)      
Net income (loss) available to common stockholders, diluted:245(58)(59)(57)(54)(46)(58)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net income (loss):247(58)(59)(57)(54)(46)(58)
Comprehensive income (loss):247(58)(59)(57)(54)(46)(58)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(2)(1)(0)0(0)(0)1
Comprehensive income (loss), net of tax, attributable to parent:245(59)(59)(56)(54)(47)(58)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: